
Barry A. Chestnut
Examiner (ID: 7338, Phone: (571)270-3546 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671, 1672 |
| Total Applications | 1132 |
| Issued Applications | 817 |
| Pending Applications | 79 |
| Abandoned Applications | 254 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18792685
[patent_doc_number] => 11826418
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-11-28
[patent_title] => Virus-like particle (VLP)-based vaccine against CVB4
[patent_app_type] => utility
[patent_app_number] => 18/151409
[patent_app_country] => US
[patent_app_date] => 2023-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 28
[patent_no_of_words] => 4616
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151409
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/151409 | Virus-like particle (VLP)-based vaccine against CVB4 | Jan 5, 2023 | Issued |
Array
(
[id] => 18794188
[patent_doc_number] => 11827946
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Methods and systems for analysis of samples containing particles used for gene delivery
[patent_app_type] => utility
[patent_app_number] => 18/087772
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 16
[patent_no_of_words] => 17612
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18087772
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/087772 | Methods and systems for analysis of samples containing particles used for gene delivery | Dec 21, 2022 | Issued |
Array
(
[id] => 18673054
[patent_doc_number] => 20230310526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => REPLICATION COMPETENT ATTENUATED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT THE EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 18/086594
[patent_app_country] => US
[patent_app_date] => 2022-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19602
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18086594
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/086594 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Dec 20, 2022 | Issued |
Array
(
[id] => 19325982
[patent_doc_number] => 12043647
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => Epitope focusing by variable effective antigen surface concentration
[patent_app_type] => utility
[patent_app_number] => 18/067525
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 46928
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067525
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067525 | Epitope focusing by variable effective antigen surface concentration | Dec 15, 2022 | Issued |
Array
(
[id] => 19165838
[patent_doc_number] => 11981726
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Antibody neutralizing human respiratory syncytial virus
[patent_app_type] => utility
[patent_app_number] => 18/065172
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 16
[patent_no_of_words] => 32102
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065172
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/065172 | Antibody neutralizing human respiratory syncytial virus | Dec 12, 2022 | Issued |
Array
(
[id] => 18725808
[patent_doc_number] => 20230340028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/059171
[patent_app_country] => US
[patent_app_date] => 2022-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059171
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059171 | Modified S1 subunit of the coronavirus spike protein | Nov 27, 2022 | Issued |
Array
(
[id] => 18725808
[patent_doc_number] => 20230340028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/059171
[patent_app_country] => US
[patent_app_date] => 2022-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059171
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059171 | Modified S1 subunit of the coronavirus spike protein | Nov 27, 2022 | Issued |
Array
(
[id] => 18725808
[patent_doc_number] => 20230340028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/059171
[patent_app_country] => US
[patent_app_date] => 2022-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059171
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059171 | Modified S1 subunit of the coronavirus spike protein | Nov 27, 2022 | Issued |
Array
(
[id] => 19724359
[patent_doc_number] => 20250027110
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES
[patent_app_type] => utility
[patent_app_number] => 18/713901
[patent_app_country] => US
[patent_app_date] => 2022-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22355
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18713901
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/713901 | COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES | Nov 27, 2022 | Pending |
Array
(
[id] => 18725808
[patent_doc_number] => 20230340028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/059171
[patent_app_country] => US
[patent_app_date] => 2022-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059171
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059171 | Modified S1 subunit of the coronavirus spike protein | Nov 27, 2022 | Issued |
Array
(
[id] => 19724390
[patent_doc_number] => 20250027141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => IMPROVED ISOTHERMAL AMPLIFICATION
[patent_app_type] => utility
[patent_app_number] => 18/713100
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18713100
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/713100 | IMPROVED ISOTHERMAL AMPLIFICATION | Nov 22, 2022 | Pending |
Array
(
[id] => 18596051
[patent_doc_number] => 20230270842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => COMPOSITIONS AND DEVICES FOR VACCINE RELEASE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/991525
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17991525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/991525 | COMPOSITIONS AND DEVICES FOR VACCINE RELEASE AND USES THEREOF | Nov 20, 2022 | Abandoned |
Array
(
[id] => 18888030
[patent_doc_number] => 11866795
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-09
[patent_title] => RNA separation and related techniques for determining viruses such as coronaviruses
[patent_app_type] => utility
[patent_app_number] => 17/987973
[patent_app_country] => US
[patent_app_date] => 2022-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 19720
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17987973
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/987973 | RNA separation and related techniques for determining viruses such as coronaviruses | Nov 15, 2022 | Issued |
Array
(
[id] => 20362823
[patent_doc_number] => 20250352635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-20
[patent_title] => RECOMBINANT FOOT-AND-MOUTH DISEASE VIRUS TYPE O FOR INDUCING ROBUST ADAPTIVE IMMUNE RESPONSE AND OVERCOMING MATERNALLY-DERIVED ANTIBODY INTERFERENCE, AND FOOT-AND-MOUTH DISEASE VACCINE COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 18/710537
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7377
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18710537
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/710537 | RECOMBINANT FOOT-AND-MOUTH DISEASE VIRUS TYPE O FOR INDUCING ROBUST ADAPTIVE IMMUNE RESPONSE AND OVERCOMING MATERNALLY-DERIVED ANTIBODY INTERFERENCE, AND FOOT-AND-MOUTH DISEASE VACCINE COMPOSITION COMPRISING SAME | Nov 10, 2022 | Pending |
Array
(
[id] => 20777944
[patent_doc_number] => 20260166137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-06-18
[patent_title] => RECOMBINANT FOOT-AND-MOUTH DISEASE TYPE A VIRUS INDUCING STRONG ADAPTIVE IMMUNE RESPONSE AND OVERCOMING INTERFERENCE FROM MATERNALLY-DERIVED ANTIBODIES, AND FOOT-AND-MOUTH DISEASE VACCINE COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 18/710511
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7150
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18710511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/710511 | RECOMBINANT FOOT-AND-MOUTH DISEASE TYPE A VIRUS INDUCING STRONG ADAPTIVE IMMUNE RESPONSE AND OVERCOMING INTERFERENCE FROM MATERNALLY-DERIVED ANTIBODIES, AND FOOT-AND-MOUTH DISEASE VACCINE COMPOSITION COMPRISING SAME | Nov 10, 2022 | Pending |
Array
(
[id] => 19652393
[patent_doc_number] => 12174173
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-24
[patent_title] => System and method for characterizing protein dimerization
[patent_app_type] => utility
[patent_app_number] => 17/979280
[patent_app_country] => US
[patent_app_date] => 2022-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 23
[patent_no_of_words] => 9733
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 174
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17979280
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/979280 | System and method for characterizing protein dimerization | Nov 1, 2022 | Issued |
Array
(
[id] => 19195309
[patent_doc_number] => 11992527
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-28
[patent_title] => Extracellular vesicles for vaccine delivery
[patent_app_type] => utility
[patent_app_number] => 18/050027
[patent_app_country] => US
[patent_app_date] => 2022-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 78
[patent_no_of_words] => 82393
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050027
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050027 | Extracellular vesicles for vaccine delivery | Oct 25, 2022 | Issued |
Array
(
[id] => 18449689
[patent_doc_number] => 20230190965
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => TREATMENT OF GLYCOGEN STORAGE DISEASE III
[patent_app_type] => utility
[patent_app_number] => 18/049296
[patent_app_country] => US
[patent_app_date] => 2022-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049296
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/049296 | TREATMENT OF GLYCOGEN STORAGE DISEASE III | Oct 24, 2022 | Abandoned |
Array
(
[id] => 18449638
[patent_doc_number] => 20230190914
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => MODIFIED IMMUNOGENIC PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/048960
[patent_app_country] => US
[patent_app_date] => 2022-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23217
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048960
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048960 | Modified immunogenic proteins | Oct 23, 2022 | Issued |
Array
(
[id] => 19165819
[patent_doc_number] => 11981706
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Parvovirus structural protein for the treatment of autoimmune diseases
[patent_app_type] => utility
[patent_app_number] => 17/938271
[patent_app_country] => US
[patent_app_date] => 2022-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 13993
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938271
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938271 | Parvovirus structural protein for the treatment of autoimmune diseases | Oct 4, 2022 | Issued |